Current state of treatment after high risk biochemical
recurrence (EMBARK) BY @RamirezBackhaus#GUARDSymposium2024@OncoAlert
🔬 EMBARK Analysis Results
• ❌ No significant differences observed in TTFD/TTCD in the BPI-SF item 3 score between treatment arms.
• ❌ No significant differences observed in TTFD/TTCD in the FACT-P total score between treatment arms.
• 📉 Post hoc analysis of sexual activity: Patient-reported outcomes in patients who were sexually active or interested in sex at baseline.
• 🧪 PRO items:
🔹 QLQ-PR25: Interest and sexual activity
🔹 FACT-P: Satisfaction with sex life, ability to feel like a man, and maintain an erection. • 📊 EMBARK. PET Performance:
🔹 RP: 36%
🔹 dRT: 56%
🔹 SRT: 60%
🔹 Overall: 46% • 📈 PRIMORDIUM study design:
🔹 6-month induction phase only
🔹 Assessments: PSA, testosterone, patient-reported outcomes.
🔹 Observational cohort: 200 patients.
#ProstateCancer #Oncology #SexualHealth #PrecisionMedicine #MedicalResearch #Health
Queridos @InfoAUCV@ResidentesAEU que estéis cerca de valencia. Os animamos a despertar vuestro interés por la neurourologia. Una charla inspiradora y un update muy enriquecedor. Jueves casadesalud
Que congreso #AEU24 tan espectacular. Gracias a la @InfoAeu por el evento y a todos los implicados. Hemos aprendido mucho y volvemos inspirados con nuevos retos
I am very honored and excited to be part of the team of authors of the EMBARK trial, published last week in the prestigious @NEJM. This work contributes to the advancement of the care of prostate cancer patients with high risk bichemical relapse: #NEJM#oncology#enzalutamide
Continuamos presentando a los miembros del Scientific Committee. El Dr. @RamirezBackhaus, la Dra. @Gemmas3108, el Dr. @ArkaitzLab, y el Dr. @raymanneh, se han sumado al proyecto GUARD de un lado y otro del Atlántico. ¡¡Bienvenidos!!
@Ryanair_ES vuelo valencia a sevilla sin aire acondicionado 32 grados dentro de avión. Un lujo; #lowcost Traveling is cáncer y lo malo es que no hay alternativas
Avances en el escenario hormonosensible en pacientes con cáncer de próstata con criterios de alto riesgo de recidiva bioquímica.
Prometedores resultados del estudio EMBARK. @RamirezBackhaus#AEU23@InfoAeu
We want to welcome you to our Webinar
Joint Meeting:
Chinese Urol. Assoc. (CUA) Session of Uro-&Andro- Technology (CSUAT) and EAU Session of Uro-Technology (ESUT):
New Technologies in Prostate Cancer
@eauesut@Uroweb@UrowebESU@ramirezbackhaus
Positive #embark trial". Our #prostatecancer#patients with high risk biochemical failure after #radicalprostatectomy or #radiotherapy will benefit from early enzalutamide. https://t.co/7Ec8zfHNWO
I WANT TO THANK MY PATIENTS WHO AGREED TO PARTICIPATE IN THE STUDY